EMA Authorised: Firmagon (degarelix) — Ferring Pharmaceuticals A/S

View source ↗

Summary

EMA authorisation of Firmagon (degarelix) for prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Ferring Pharmaceuticals A/S. Decision date: 30/03/2022